The objective of this work was to evaluate the epidermal growth factor receptor (EGFR) content in gastric cancer, its possible relationship with clinicopathological parameters of tumors and its prognostic significance. Membranous EGFR levels were examined by radioligand binding assays in 110 patients with gastric cancer. The mean follow-up period was 30.7 months. EGFR levels of tumors ranged widely, from 0.3 to 510 fmol/mg protein. EGFR levels were significantly higher (p<0.0005) in neoplastic tissue than in paired adjacent mucosa samples (median) (n= 84; 8.7 vs. 3.9 fmol/mg protein). Intratumoral EGFR levels were significantly correlated with tumor stage (p<0.05), and were higher in patients with stage III tumors (median) (7.6, 6.4, 12.3 and 7.5 fmol/mg protein for stages I, II, III and IV, respectively) . In addition, the tumor/mucosa ratios of the EGFR content were significantly higher (p<0.05) in patients with stage III tumors (1, 1.8, 3.9,  and 0.92, respectively) . Although there was no significant relationship between EGFR levels of tumors and overall survival, the results suggest a role for EGFR in tumor progression of gastric cancer. (Int J Biol Markers, 2001; 16: 183-8) 
INTRODUCTION
Epidermal growth factor receptor (EGFR) is a glycoprotein (molecular weight 170 kDa) that can be divided into an extracellular domain binding the epidermal growth factor (EGF) as well as the transforming growth factor-alpha (TGF-alpha), a short transmembrane domain, and an intracellular domain carrying tyrosine kinase activity (1) . EGF and TGF-alpha are produced locally in many tissues as local growth factors, and through EGFR stimulate DNA synthesis and cell growth in various systems, including the gastrointestinal tract (2) . In addition, it has been demonstrated that EGFR is not only important in cell proliferation but in a variety of processes likely to be important for tumor progression such as cell motility, cell adhesion, invasion, cell survival, and angiogenesis (3) . The EGFR gene is amplified and overexpressed in a variety of solid human cancers including breast, colorectal, brain, esophageal, non-small cell lung, ovarian, head and neck, and bladder carcinomas, and it has been associated with various features of more aggressive disease and poor prognosis of the patients in numerous studies (4) .
Expression of the EGFR in human gastric cancer has also been demonstrated using several methods, including immunohistochemistry (5-9), radioligand binding assays (10, 11) , Western and Northern blotting (6, 12) , and measurement of EGFR transcripts (13) (14) (15) (16) . In addition, it has been reported that the cumulative survival rate of gastric cancer patients with EGFR gene amplification was significantly lower than that of patients without amplification (15, 16) . Similarly, immunohistochemical studies have suggested that patients with EGFR-positive gastric carcinomas also had a poorer prognosis than did negative cases (7, 8, 17) .
The aims of the present study were i) to analyze, with a radioligand binding assay, EGFR measurement in gastric primary carcinomas and in surrounding mucosa; ii) to assess the relationships of EGFR content with the classical clinicopathological characteristics of tumors; and iii) to evaluate the prognostic value of this membrane receptor in gastric cancer patients.
MATERIAL AND METHODS

Patients
This prospective study included a series of 110 patients with primary gastric adenocarcinomas who consecutively underwent surgical resection. Samples of gastric carcinomas were obtained from all patients and adjacent mucosa samples were obtained from 84 of them. Age ranged from 42 to 85 years (average, 68.3 years). Patient characteristics regarding age, sex, tumor location, histological type, histological grade, and tumor stage are listed in Table I . Each case was staged according to the TNM classification criteria advocated by the UICC (18) . The histological type of the tumors was determined according to Lauren's criteria (19) .
All patients were evaluated for disease recurrence and survival status by clinical and biological examinations (blood counts, liver examination test and serum carcinoembryonic antigen), upper gastrointestinal endoscopic assessment, and diagnostic imaging (chest radiograph, ultrasonography, computed tomography, or 
Tissue processing and EGFR assay
Samples were removed from the tumors, avoiding grossly necrotic tissue. Adjacent mucosa samples were obtained from 84 cases. These mucosa samples were macroscopically and microscopically free from neoplastic growth. Immediately after surgical resection samples were processed for pathological examination while the remainder were washed with a cold saline solution, divided into aliquots, rapidly transported on ice to the laboratory, and stored at -70°C pending biochemical studies.
Specimens from neoplastic and normal surrounding tissues were processed at the same time. They were pulverized with a microdismembrator (Braun, Melsungen, Germany) at -70°C and homogenized in Tris hydrochloride (Tris 10 mmol/L, ethylenediamine tetraacetic acid 1.5 mmol/L, 10% glycerol, 0.1% monothioglycerol) at pH 7.4. Homogenates were centrifuged at 800g for 10 min at 4°C and the supernatant was ultracentrifuged at 100.000g for 60 min at 4°C. The obtained membrane pellets were resuspended in Tris buffer and stored at -70°C until analysis. Then the membrane pellets were homogenized in a glass-teflon potter. The protein concentration was determined by the Lowry method (20) . EGFR assays were performed by radioligand bind-ing at a single saturation dose using a commercially available kit (Vienna Lab). For EGFR Scatchard assay EGF alpha was obtained from male mouse submaxillary glands, enzymatically radioiodinated using solid phasecoupled lactoperoxidase/glucose oxidase (Enzymobeads TM ). With this method, the product is purified by chromatography on a C18-reversed phase column (21) . The control for normal tissue consists of lyophilized human placenta membranes stabilized with BSA, and the control for tumor tissue is breast carcinoma, as previously described (22, 23) . Briefly, 75 µL aliquots of cell membrane preparation are incubated with 125 I-EGF at a concentration of 0.5 nM in the absence (=total binding) or presence (=unspecific binding) of a 200-fold excess of unlabeled ("cold") EGF in a competitive manner. After incubation, free EGF is separated from receptor-bound EGF by the addition of precipitation reagents (gamma globulin, polyethylene glycol) and low-speed centrifugation. Bound 125 I-EGF is determined by gamma counting. Subtraction of unspecific binding from total binding yields specific binding, from which the concentration of EGFR is calculated as fmol/mg protein.
Statistical analysis
EGFR content was expressed as median (range). The differences in EGFR content between tumor tissues and paired adjacent mucosa samples were compared using Wilcoxon's signed rank test. Patients were subdivided into groups based on different clinical and pathological parameters. The EGFR content between groups was compared using the Mann-Whitney and Kruskall-Wallis tests. Differences in the positivity percentages were calculated using the chi-square test. The relapse-free and overall survival probabilities were calculated using the Kaplan-Meier method (24) . Differences between curves were evaluated with the log-rank test (25) . Differences were considered significant at p <0.05.
RESULTS
There was a wide variability of membranous levels of EGFR in neoplastic tissues (0.3-510 fmol/mg protein). EGFR levels in neoplastic tisues were significantly higher (p<0.0005) than those found in paired adjacent mucosa samples (n=84; 8.7 (0.3-389) vs 3.9 (0.4-50.7) fmol/mg protein). Comparison of pairs of mucosa and carcinoma samples showed an increase in EGFR levels in 51 of 84 carcinomas, no change in six, and a decrease in 27 carcinomas. Table I shows the distribution of EGFR levels in 110 tumors in relation to patient and tumor characteristics including age, sex, tumor location, stage, histological type and tumor grade. Statistical analysis showed that EGFR levels were significantly correlated with clinical tumor stage; EGFR levels were highest in patients with stage III tumors (7.6 (1-42.5), 6.4 (0.3-141), 12.3 (1-389) and 7.5 (1-540) fmol/mg protein for stage I, II, III and IV, respectively). In addition, as can be seen in Figure 1 , the tumor/mucosa ratios of the EGFR content were significantly higher (p<0.05) in patients with stage III tumors (1 (0.07-9.5), 1.83 (0.02-13.3), 3.9 (0.17-91.3), 0.92 (0.12-18.9) fmol/mg protein for stage I, II, III and IV, respectively). However, there was no correlation between tumor EGFR content or tumor/mucosa ratio and age, sex, tumor location, histological type and grade (Tab. I and Fig. 1) .
The potential association between EGFR content in neoplastic tissues and overall survival was prospectively evaluated in the 110 patients included in the present study. The patients were divided into three equally sized groups according to tumor EGFR levels. Patients with high tumor EGFR levels had a shorter overall survival than patients with low or intermediate EGFR levels. However, there was no significant difference between overall survival curves in the total patient group, the group of patients with resectable tumors and those with unresectable tumors (Fig. 2) .
DISCUSSION
The results of the present study demonstrate a wide variability of EGFR levels in gastric carcinomas, and show that these tumor contents are significantly higher than those found in adjacent gastric mucosa. The variability of the tumor EGFR levels seems to correspond to the biological heterogeneity of gastric carcinomas, and these high levels, which were also reported by two previous studies based on radioligand binding assays (10, 11) , seem to reflect specific molecular changes related to neoplastic transformation. In this regard there is experimental evidence from various sources suggesting that EGFR plays a crucial role in regulating the growth of gastric cancer. Growth inhibition of three human gastric (R1 or R2) . The patients were divided into three equally sized groups according to EGFR levels. Differences in overall survival curves were not significant (log-rank test).
cancer cell lines has been demonstrated both in vitro and in vivo by the suppression of EGFR protein levels via an antisense mRNA (26, 27) . Other experimental studies have shown that EGFR plays an important role in various basic processes related to tumor progression such as cell proliferation, cell survival, angiogenesis, cell motility, cell adhesion and tumor invasion (3) . In relation to the latter finding, a positive correlation was observed between the depth of tumor invasion and the expression of EGFR in human gastric carcinomas (6, 16) . Similarly, the results of the present study showed high EGFR levels in stage III tumors, which suggests a biological relationship between the high membrane protein content and an invasive phenotype in gastric cancer. It has also been reported that a significant correlation exists between EGFR expression and other parameters indicative of tumor aggressiveness in gastric cancer including a poor differentiation grade (7, 17) , high proliferating activity of tumor cells (7, 8) , and the occurrence of lymph node metastases (8) .
In agreement with the evidence pointing to a putative role of EGFR in the progression of gastric cancer, different studies have reported a significant relationship between the expression of this membrane protein examined by immunohistochemistry (7, 8, 17) or in situ hybridization (15, 16) and a poor prognosis. In the present work, although high tumor EGFR levels measured by immunoradiometric assay were correlated with a poor survival in gastric cancer patients, this association was not significant in the different patient subgroups. However, large studies assessing the independent prognostic impact of EGFR in gastric cancer by multivariate analysis will be necessary to further elucidate this issue.
On the other hand, the complex biology of EGFR provides potential opportunities for EGFR-targeted treatments. One of the most promising current strategies in cancer therapy involves the use of a variety of agents to inhibit EGFR activation, including enzyme inhibitors, antibodies or antisense oligonucleotides (3, 28) . Thus, tumor EGFR content could be a valuable biomarker for the selection of patients to be treated with EGFR-targeted anticancer agents.
In conclusion, the results of the present investigation, which should be confirmed by further studies, suggest that EGFR determination may play a role in the management of gastric cancer.
